One of Peter Navarro's jobs at the White House is making sure an eventual coronavirus vaccine gets widely manufactured and distributed. He promises that “we won't be in a situation where we have too little.” ...
Price swings and volatility are high this year are extreme, which means we pear back the number of trades we make, and reduce position size to protect us....
Stocks slid following the Federal Reserve’s monetary policy decision, in which policymakers highlighted the ongoing economic concerns spurred by the coronavirus pandemic and measures taken to contain it....
Regeneron Pharmaceuticals, Inc (REGN) said Thursday it started the first human clinical trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID-19.The REGN-COV2 clinical program will consist of four separate study populations: hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, individuals that are at high-risk of exposure, such as healthcare workers or first responders, and people with close exposure to a COVID-19 patient. The placebo-controlled trials will be conducted at multiple sites."We have created a unique anti-viral antibody cocktail with the potential both to prevent and treat infection, and also to preempt viral 'escape,' a critical precaution in the midst of an ongoing global pandemic," said George D. Yancopoulos, Co-Founder and Chief Scientific Officer of Regeneron. "REGN-COV2 could have a major impact on public health by slowing spread of the virus and providing a needed treatment for those already sick – and could be available much sooner...
